Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Stallergenes SA

+ Add to Watchlist

5S6:GR

55.835 EUR 0.065 0.12%

As of 07:17:58 ET on 05/27/2015.

Snapshot for Stallergenes SA (5S6)

Open: 56.256 Day's Range: 55.731 - 56.256 Volume: 0
Previous Close: 55.770 52wk Range: 46.150 - 59.030 1-Yr Rtn: +4.64%

Stock Chart for 5S6

No chart data available.
  • 5S6:GR 55.835
  • 1D
  • 1M
  • 1Y
55.770
Interactive 5S6 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for 5S6

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) 17.7367
Relative P/E vs. DAX -
Earnings Per Share (EUR) (ttm) -
Est. EPS (EUR) (12/2015) 3.1480
Est. PEG Ratio -
Market Cap (M EUR) 773.70
Shares Outstanding (M) 13.86
30 Day Average Volume 5
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 1.34%
Cash Dividend (EUR) 0.7500
Dividend Ex-Date
5 Year Dividend Growth 10.76%
Next Earnings Announcement 07/22/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for 5S6

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for 5S6

Stallergenes is an international biopharmaceutical company dedicated to the treatment of allergy-related respiratory diseases using allergy immunotherapy. The company is involved in the research and development of therapeutic sublingual immunotherapy tablets.

Christian ChavyChief Executive OfficerPeter BuhlerChief Financial Officer
Robert ZeldinSenior VP:Global Clinical DevRichard LejosneSenior VP:Human Resources
More Company Profile & Key Executives for 5S6

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil